Development
Sarepta Therapeutics, Inc.
SRPT
$16.26
-$0.49-2.93%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -535.98M | -690.88M | -907.68M | -1.12B | -703.49M |
| Total Depreciation and Amortization | 44.40M | 43.58M | 43.35M | 42.45M | 41.86M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 471.68M | 490.76M | 592.83M | 764.21M | 375.75M |
| Change in Net Operating Assets | -481.09M | -382.19M | -217.49M | -125.01M | -39.47M |
| Cash from Operations | -500.99M | -538.73M | -488.99M | -433.57M | -325.35M |
| Capital Expenditure | -76.11M | -65.03M | -43.59M | -34.76M | -30.82M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.70M | -26.62M | 181.63M | -213.83M | -1.02B |
| Cash from Investing | -165.80M | -91.65M | 138.04M | -248.58M | -1.05B |
| Total Debt Issued | -- | 0.00 | 1.13B | 1.13B | 1.13B |
| Total Debt Repaid | -- | 0.00 | -823.23M | -823.23M | -823.23M |
| Issuance of Common Stock | 51.25M | 60.61M | 58.61M | 53.09M | 30.04M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 73.76M | 73.20M | -27.95M | -27.95M | -101.70M |
| Cash from Financing | 125.00M | 133.81M | 334.83M | 329.31M | 232.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -541.79M | -496.57M | -16.11M | -352.84M | -1.14B |